Cargando…
Dynamic contrast-enhanced magnetic resonance imaging features and apparent diffusion coefficient value of HER2-positive/HR-negative breast carcinoma
BACKGROUND: According to hormone receptor (HR) status, human epidermal growth factor 2 positive (HER2+) breast carcinoma can be divided into HR− and HR+, with different treatment and prognosis. We analyzed the dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) findings, apparent diffusio...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423352/ https://www.ncbi.nlm.nih.gov/pubmed/37581065 http://dx.doi.org/10.21037/qims-22-1318 |
_version_ | 1785089429776367616 |
---|---|
author | Chen, Peipei Zhao, Suhong Guo, Weihua Shao, Guangrui |
author_facet | Chen, Peipei Zhao, Suhong Guo, Weihua Shao, Guangrui |
author_sort | Chen, Peipei |
collection | PubMed |
description | BACKGROUND: According to hormone receptor (HR) status, human epidermal growth factor 2 positive (HER2+) breast carcinoma can be divided into HR− and HR+, with different treatment and prognosis. We analyzed the dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) findings, apparent diffusion coefficient (ADC) value and the combination of DCE-MRI and ADC value of HER2+/HR− breast carcinoma. METHODS: Totally 259 cases (96 HR−, 163 HR+) of pathologically verified HER2+ breast carcinoma were collected. Patients underwent DCE-MRI and diffusion weighted imaging (DWI). The morphological characteristics, internal enhancement characteristics, early enhancement rate (EER), and time-signal intensity curves (TIC) were recorded, and ADC values were measured. The relationship between each feature and HER2+/HR− breast cancer was analyzed. Area under the cures (AUC) was used to compare diagnostic performance of DCE-MRI, ADC value and the combination of DCE-MRI and ADC value. RESULTS: HER2+/HR− breast cancer presented as non-mass enhancement (NME), mass with NME, whereas HER2+/HR+ breast cancer presented as mass (P<0.001). HR− cases showed a round or oval shape with circumscribed margins, whereas HR+ cases showed an irregular mass with irregular or spiculated margins (P=0.001, P=0.028). The size of the mass, the internal enhancement characteristics, EER, and TIC did not differ significantly between the two HER2+ breast carcinomas. The ADC values for HR− and HR+ breast cancers were [1.2 (1.14, 1.33)] ×10(−3) mm(2)/s and [1.0 (0.89, 1.11)] ×10(−3) mm(2)/s, respectively, which were statistically significant (Z=−9.119, P<0.001). The ADC value can be used for diagnosing HER2+/HR− breast carcinoma, with the threshold value of 1.095×10(−3) mm(2)/s [negative predictive value (NPV) of 89.8%, sensitivity of 86.5% and specificity of 70.6%]. The AUCs of ADC value, DCE-MRI, and DCE-MRI combined with ADC value were 0.839, 0.689 and 0.860, respectively. AUC of the DCE-MRI combined with ADC value was significantly higher than DCE-MRI alone (P<0.0001). CONCLUSIONS: The diagnostic performance of the DCE-MRI combined with ADC value was good in diagnosing HER2+/HR− breast cancers. MRI is an effective tool in diagnosing HER2+/HR− breast carcinoma, which will help select the clinical treatment plan and determine the prognosis. |
format | Online Article Text |
id | pubmed-10423352 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-104233522023-08-14 Dynamic contrast-enhanced magnetic resonance imaging features and apparent diffusion coefficient value of HER2-positive/HR-negative breast carcinoma Chen, Peipei Zhao, Suhong Guo, Weihua Shao, Guangrui Quant Imaging Med Surg Original Article BACKGROUND: According to hormone receptor (HR) status, human epidermal growth factor 2 positive (HER2+) breast carcinoma can be divided into HR− and HR+, with different treatment and prognosis. We analyzed the dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) findings, apparent diffusion coefficient (ADC) value and the combination of DCE-MRI and ADC value of HER2+/HR− breast carcinoma. METHODS: Totally 259 cases (96 HR−, 163 HR+) of pathologically verified HER2+ breast carcinoma were collected. Patients underwent DCE-MRI and diffusion weighted imaging (DWI). The morphological characteristics, internal enhancement characteristics, early enhancement rate (EER), and time-signal intensity curves (TIC) were recorded, and ADC values were measured. The relationship between each feature and HER2+/HR− breast cancer was analyzed. Area under the cures (AUC) was used to compare diagnostic performance of DCE-MRI, ADC value and the combination of DCE-MRI and ADC value. RESULTS: HER2+/HR− breast cancer presented as non-mass enhancement (NME), mass with NME, whereas HER2+/HR+ breast cancer presented as mass (P<0.001). HR− cases showed a round or oval shape with circumscribed margins, whereas HR+ cases showed an irregular mass with irregular or spiculated margins (P=0.001, P=0.028). The size of the mass, the internal enhancement characteristics, EER, and TIC did not differ significantly between the two HER2+ breast carcinomas. The ADC values for HR− and HR+ breast cancers were [1.2 (1.14, 1.33)] ×10(−3) mm(2)/s and [1.0 (0.89, 1.11)] ×10(−3) mm(2)/s, respectively, which were statistically significant (Z=−9.119, P<0.001). The ADC value can be used for diagnosing HER2+/HR− breast carcinoma, with the threshold value of 1.095×10(−3) mm(2)/s [negative predictive value (NPV) of 89.8%, sensitivity of 86.5% and specificity of 70.6%]. The AUCs of ADC value, DCE-MRI, and DCE-MRI combined with ADC value were 0.839, 0.689 and 0.860, respectively. AUC of the DCE-MRI combined with ADC value was significantly higher than DCE-MRI alone (P<0.0001). CONCLUSIONS: The diagnostic performance of the DCE-MRI combined with ADC value was good in diagnosing HER2+/HR− breast cancers. MRI is an effective tool in diagnosing HER2+/HR− breast carcinoma, which will help select the clinical treatment plan and determine the prognosis. AME Publishing Company 2023-05-12 2023-08-01 /pmc/articles/PMC10423352/ /pubmed/37581065 http://dx.doi.org/10.21037/qims-22-1318 Text en 2023 Quantitative Imaging in Medicine and Surgery. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Chen, Peipei Zhao, Suhong Guo, Weihua Shao, Guangrui Dynamic contrast-enhanced magnetic resonance imaging features and apparent diffusion coefficient value of HER2-positive/HR-negative breast carcinoma |
title | Dynamic contrast-enhanced magnetic resonance imaging features and apparent diffusion coefficient value of HER2-positive/HR-negative breast carcinoma |
title_full | Dynamic contrast-enhanced magnetic resonance imaging features and apparent diffusion coefficient value of HER2-positive/HR-negative breast carcinoma |
title_fullStr | Dynamic contrast-enhanced magnetic resonance imaging features and apparent diffusion coefficient value of HER2-positive/HR-negative breast carcinoma |
title_full_unstemmed | Dynamic contrast-enhanced magnetic resonance imaging features and apparent diffusion coefficient value of HER2-positive/HR-negative breast carcinoma |
title_short | Dynamic contrast-enhanced magnetic resonance imaging features and apparent diffusion coefficient value of HER2-positive/HR-negative breast carcinoma |
title_sort | dynamic contrast-enhanced magnetic resonance imaging features and apparent diffusion coefficient value of her2-positive/hr-negative breast carcinoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423352/ https://www.ncbi.nlm.nih.gov/pubmed/37581065 http://dx.doi.org/10.21037/qims-22-1318 |
work_keys_str_mv | AT chenpeipei dynamiccontrastenhancedmagneticresonanceimagingfeaturesandapparentdiffusioncoefficientvalueofher2positivehrnegativebreastcarcinoma AT zhaosuhong dynamiccontrastenhancedmagneticresonanceimagingfeaturesandapparentdiffusioncoefficientvalueofher2positivehrnegativebreastcarcinoma AT guoweihua dynamiccontrastenhancedmagneticresonanceimagingfeaturesandapparentdiffusioncoefficientvalueofher2positivehrnegativebreastcarcinoma AT shaoguangrui dynamiccontrastenhancedmagneticresonanceimagingfeaturesandapparentdiffusioncoefficientvalueofher2positivehrnegativebreastcarcinoma |